Limits...
Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.

Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H - Cancer Sci. (2014)

Bottom Line: However, resistance to HER2-targeted therapy remains a major clinical problem.HER2-positive breast tumors are predominantly positive for CD24, suggesting that the expression of the two molecules is related.Flow cytometry thus revealed that the percentage of CD24-positive cells was markedly higher in the HER2-positive fraction than in the HER2-negative fraction.

View Article: PubMed Central - PubMed

Affiliation: Division of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan; Department of Breast Oncology, Tokyo Medical University, Tokyo, Japan.

Show MeSH

Related in: MedlinePlus

Positive relation between human epidermal growth factor receptor 2 (HER2) and CD24 expression among HER2-expressing breast cancer cell lines. (a) Flow cytometric analysis of CD44 and CD24 expression in HER2-positive breast cancer cell lines. The percentage of CD44+CD24− cells is indicated in the right lower panel. (b) Cells were stained with antibodies to HER2, to CD44 and to CD24 and then gated on the basis of HER2 expression. The top 20% fraction of HER2-high cells (red boxes) and the bottom 20% fraction of HER2-low/- cells (blue boxes) were gated in each cell line. The histograms show the expression level of CD24 in these two fractions for each cell line. (c) Comparison of the expression of CD44 and CD24 between the HER2-high and HER2-low/- fractions of each cell line isolated as in (b). The percentage of CD24-positive cells is shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317915&req=5

fig04: Positive relation between human epidermal growth factor receptor 2 (HER2) and CD24 expression among HER2-expressing breast cancer cell lines. (a) Flow cytometric analysis of CD44 and CD24 expression in HER2-positive breast cancer cell lines. The percentage of CD44+CD24− cells is indicated in the right lower panel. (b) Cells were stained with antibodies to HER2, to CD44 and to CD24 and then gated on the basis of HER2 expression. The top 20% fraction of HER2-high cells (red boxes) and the bottom 20% fraction of HER2-low/- cells (blue boxes) were gated in each cell line. The histograms show the expression level of CD24 in these two fractions for each cell line. (c) Comparison of the expression of CD44 and CD24 between the HER2-high and HER2-low/- fractions of each cell line isolated as in (b). The percentage of CD24-positive cells is shown.

Mentions: We next examined the expression of HER2, CD24 and CD44 in five HER2-positive breast cancer cell lines: BT-474, HCC202, SKBR3, ZR-75-1 and HCC1569. Flow cytometry showed that the CD44+CD24− subpopulation constituted 2.65%, 0.057%, 0.143%, 1.42% and 91.7% of cells in these lines, respectively (Fig. 4a). Next, we measured CD24 expression levels in the top 20% fraction of HER2-high cells and the bottom 20% fraction of HER2-low/- cells of each cell line (Fig. 4b). For BT-474, which has an amplification of HER2 gene, the CD24-positive subpopulation was 97.1% in the HER2-high fraction but 73.4% in the HER2-low/- fraction. For ZR-75-1, which has a normal level of HER2, the proportion of CD24-positive cells was 97.2% in the HER2-high fraction but only 27.4% in the HER2-low/- fraction (Fig. 4c). A similar pattern was apparent for the other three HER2-amplified cell lines. The expression of CD24 was thus higher in HER2-high cells than in HER2-low/- cells for all five breast cancer cell lines.


Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.

Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H - Cancer Sci. (2014)

Positive relation between human epidermal growth factor receptor 2 (HER2) and CD24 expression among HER2-expressing breast cancer cell lines. (a) Flow cytometric analysis of CD44 and CD24 expression in HER2-positive breast cancer cell lines. The percentage of CD44+CD24− cells is indicated in the right lower panel. (b) Cells were stained with antibodies to HER2, to CD44 and to CD24 and then gated on the basis of HER2 expression. The top 20% fraction of HER2-high cells (red boxes) and the bottom 20% fraction of HER2-low/- cells (blue boxes) were gated in each cell line. The histograms show the expression level of CD24 in these two fractions for each cell line. (c) Comparison of the expression of CD44 and CD24 between the HER2-high and HER2-low/- fractions of each cell line isolated as in (b). The percentage of CD24-positive cells is shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317915&req=5

fig04: Positive relation between human epidermal growth factor receptor 2 (HER2) and CD24 expression among HER2-expressing breast cancer cell lines. (a) Flow cytometric analysis of CD44 and CD24 expression in HER2-positive breast cancer cell lines. The percentage of CD44+CD24− cells is indicated in the right lower panel. (b) Cells were stained with antibodies to HER2, to CD44 and to CD24 and then gated on the basis of HER2 expression. The top 20% fraction of HER2-high cells (red boxes) and the bottom 20% fraction of HER2-low/- cells (blue boxes) were gated in each cell line. The histograms show the expression level of CD24 in these two fractions for each cell line. (c) Comparison of the expression of CD44 and CD24 between the HER2-high and HER2-low/- fractions of each cell line isolated as in (b). The percentage of CD24-positive cells is shown.
Mentions: We next examined the expression of HER2, CD24 and CD44 in five HER2-positive breast cancer cell lines: BT-474, HCC202, SKBR3, ZR-75-1 and HCC1569. Flow cytometry showed that the CD44+CD24− subpopulation constituted 2.65%, 0.057%, 0.143%, 1.42% and 91.7% of cells in these lines, respectively (Fig. 4a). Next, we measured CD24 expression levels in the top 20% fraction of HER2-high cells and the bottom 20% fraction of HER2-low/- cells of each cell line (Fig. 4b). For BT-474, which has an amplification of HER2 gene, the CD24-positive subpopulation was 97.1% in the HER2-high fraction but 73.4% in the HER2-low/- fraction. For ZR-75-1, which has a normal level of HER2, the proportion of CD24-positive cells was 97.2% in the HER2-high fraction but only 27.4% in the HER2-low/- fraction (Fig. 4c). A similar pattern was apparent for the other three HER2-amplified cell lines. The expression of CD24 was thus higher in HER2-high cells than in HER2-low/- cells for all five breast cancer cell lines.

Bottom Line: However, resistance to HER2-targeted therapy remains a major clinical problem.HER2-positive breast tumors are predominantly positive for CD24, suggesting that the expression of the two molecules is related.Flow cytometry thus revealed that the percentage of CD24-positive cells was markedly higher in the HER2-positive fraction than in the HER2-negative fraction.

View Article: PubMed Central - PubMed

Affiliation: Division of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan; Department of Breast Oncology, Tokyo Medical University, Tokyo, Japan.

Show MeSH
Related in: MedlinePlus